



GAMP Good Practice Guide

Manufacturing Execution Systems – A Strategic and Program Management Approach



GAMP Good Practice Guide

Manufacturing Execution Systems – A Strategic and Program Management Approach

Disclaimer:

This Guide is meant to assist pharmaceutical organizations and related industry organizations in determining a common understanding of the concept and principles of Control and Compliance of Manufacturing Execution Systems. The International Society for Pharmaceutical Engineering (ISPE) cannot ensure and does not warrant that systems managed in accordance with this Guide will be acceptable to regulatory authorities. Further, this Guide does not replace the need for hiring professional engineers or technicians.

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© Copyright ISPE 2010. All rights reserved.

All rights reserved. No part of this document may be reproduced or copied in any form or by any means – graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems – without written permission of ISPE.

All trademarks used are acknowledged.

ISBN 1-931879-75-3

Preface

The ISPE GAMP® Good Practice Guide: Manufacturing Execution Systems – A Strategic and Program Management Approach, was created to help to facilitate the planning, development, and testing of Manufacturing Execution Systems (MES) that may be used to support manufacturing in life sciences organizations.

This Guide is intended to help bridge the gap between the ISPE GAMP® Good Practice Guide: Global Information Systems Control and Compliance and the ISPE GAMP® Good Practice Guide: Validation of Process Control Systems for supporting and maintaining MES environments. The ISPE GAMP® Good Practice Guide: Manufacturing Execution Systems – A Strategic and Program Management Approach should be read in conjunction with these Guides.

GAMP® guidance aims to achieve computerized systems that are fit for intended use and meet current regulatory requirements, by building upon existing industry good practice in an efficient and effective manner. This Guide has been developed by pharmaceutical industry professionals to meet these goals and principles.

This Guide takes a life cycle approach to examining MES, not as an application, but as a collection or domain of manufacturing related functions that integrates business and process controls, information flow, and human interaction to facilitate the operation of an organization.

As individual systems evolve to become broader in scope, a system considered to be business-oriented may have functionality which connects to Manufacturing Operations and potentially affects product quality. Therefore, the integration of functions may require the application of testing principles for process control systems to a system considered to be business-oriented. The definition of a 'business system' may become difficult, and it may become necessary to create logical boundaries around functionality across systems to define categories of use and criticality.

The domain approach presented in this Guide provides an approach to manage life cycles for the integrated manufacturing environment.

The authors of this Guide have built upon ANSI/ISA 95.00.01-2000, Enterprise-Control System Integration, Part 1; Models and Terminology, an industry independent standard for improved integration of manufacturing through communication that defines common terminology and a consistent set of models that emphasize good practices for integration of control systems with other enterprise systems.

Acknowledgements

This Guide was developed by a Task Team under the ISPE GAMP COP Special Interest Group **co-leadership** of **Gregory Ruklic** and **Paul Irving**.

Section Writers and Reviewers

This Guide was produced by a dedicated team of subject matter experts from across the industry. The following Core Team Members took lead roles in the authoring of this document.

Joseph deSpautz	Global Life Sciences	USA
Karen Donaldson	Pfizer Inc.	USA
Justin Iovino	Cognizant Technology Solutions	USA
Paul Irving	Aptitude UK Limited	United Kingdom
Ed Kanczewski	Process and Compliance Management	USA
Kenneth S. Kovacs	Independent	USA
David Lerner	PA Consulting	USA
Allan Pfitzenmaier	Vectech Pharmaceutical Consultants, Inc.	USA
Gregory Ruklic	Wyeth	USA

The Task Team Leaders would like to express their grateful thanks to the following Team Members for their contribution of additional materials and as technical reviewers of the Guide:

Stephen Elms	Novartis Pharma AG	Switzerland
David Emerson	Yokogawa	USA
Jeanette Ewen	Felten S.A.	Luxembourg
Malcolm Granger	MJA International Ltd.	United Kingdom
Jerry Hare	Voice of Compliance, LLC	USA
Philip Rees	CIS Ltd.	United Kingdom
Dudley Williams	VFMS Ltd.	United Kingdom

The Task Team Leaders additionally wish to thank Rockwell Automation and GlaxoSmithKline for supporting employee efforts during authoring and review.

Special thanks go to Chris Clark, Winnie Cappucci, Paige Kane, and Randy Perez for their tireless support of this Guide.

Special thanks also go to Colin Jones, Tony Margetts, and Sion Wyn for their coaching and editorial contributions.

Many other individuals reviewed and provided comments during the preparation of this Guide; although they are too numerous to list here, their input is greatly appreciated.



**ENGINEERING
PHARMACEUTICAL
INNOVATION**

ISPE Headquarters

3109 W. Dr. Martin Luther King Jr. Blvd., Suite 250, Tampa, Florida 33607 USA
Tel: +1-813-960-2105, Fax: +1-813-264-2816

ISPE Asia Pacific Office

73 Bukit Timah Road, #04-01 Rex House, Singapore 229832
Tel: +65-6496-5502, Fax: +65-6336-6449

ISPE China Office

Suite 2302, Wise Logic International Center
No. 66 North Shan Xi Road, Shanghai, China 200041
Tel +86-21-5116-0265, Fax +86-21-5116-0260

ISPE European Office

Avenue de Tervueren, 300, B-1150 Brussels, Belgium
Tel: +32-2-743-4422, Fax: +32-2-743-1550

www.ISPE.org

Table of Contents

1	Introduction	9
1.1	Overview	9
1.2	Purpose.....	9
1.3	Scope.....	10
1.4	Benefits	10
1.5	Objectives	11
1.6	Key Concepts.....	12
1.7	Structure of Guidance	15
2	Approach to Achieving Control and Compliance	17
2.1	Strategy for MES.....	17
2.2	MES Life Cycle	19
2.3	Quality Risk Management.....	20
3	Project Phase	21
3.1	Introduction	21
3.2	Planning.....	23
3.3	Requirements Definition.....	28
3.4	Specification and Design	29
3.5	Configuration and Customization.....	30
3.6	Implementation	31
3.7	Verification	32
3.8	Data Migration.....	35
3.9	Reporting and Release	37
3.10	Supporting Processes.....	38
4	Operation Phase	43
4.1	Introduction	43
4.2	Operational Change Control and Configuration Management.....	43
4.3	Security.....	44
4.4	Performance Monitoring.....	44
4.5	Backup and Recovery of Software and Data	44
4.6	Record Retention, Archive, and Retrieval	44
4.7	Business Continuity and Contingency Planning	44
4.8	Periodic Review	45
5	Appendix 1 – Coordination of Compliance, Project, and Operations Activities for MES	47
5.1	Introduction	47
5.2	Structuring a Program.....	47
5.3	Program Responsibilities	48

- 6 Appendix 2 – MES Planning..... 51**
 - 6.1 Introduction 51
 - 6.2 Challenges 52
 - 6.3 Business Drivers 53
 - 6.4 Program Planning 54
 - 6.5 Strategic Planning 54
 - 6.6 Functional Domains 58
 - 6.7 Application Selection 58
 - 6.8 MES Implementation Plan 58
 - 6.9 Risk Considerations 58
 - 6.10 Roles and Responsibilities 58
 - 6.11 Regulatory 60
 - 6.12 Data Management Planning 60
 - 6.13 System Architecture 60
 - 6.14 Funding 61

- 7 Appendix 3 – Domain Approach..... 63**
 - 7.1 Introduction 63
 - 7.2 Applying Domains to Systems Design 64
 - 7.3 Domain Impact on Risk Management and Verification 66
 - 7.4 Domain Approach Implementation for Existing Systems 67
 - 7.5 Summary of Domain Approach Benefits 67
 - 7.6 Expanding the Genealogy Example 68

- 8 Appendix 4 – Developing an MES Implementation Strategy 69**
 - 8.1 Introduction 69
 - 8.2 Considerations and Concepts for Strategy Development 69
 - 8.3 Horizontal Implementation Strategy 70
 - 8.4 Vertical Implementation Strategy 71
 - 8.5 Application Control Strategies 72
 - 8.6 Core Team Activities 74
 - 8.7 Deployment of MES Core Functionality 75
 - 8.8 Phased Deployment 76
 - 8.9 System Controls during Deployments 77
 - 8.10 Other Considerations 77
 - 8.11 Life Cycle Phase Relationships 77

- 9 Appendix 5 – An Approach to Application and System Selection 79**
 - 9.1 Introduction 79
 - 9.2 Development of the Tactical Approach 79
 - 9.3 Scope and Justification 82

- 10 Appendix 6 – System Integration: Interfaces and Touch Points 85**
 - 10.1 Introduction 85
 - 10.2 Data 85
 - 10.3 Middleware 85
 - 10.4 ERP Interface 86
 - 10.5 Process Automation 87
 - 10.6 Batch Systems 88
 - 10.7 LIMS 88
 - 10.8 Interface Issues for Electronic Records and Signatures 89

11	Appendix 7 – Electronic Production Record Systems	91
11.1	Introduction	91
11.2	Establishing Equivalent Electronic Functionality	92
11.3	Ancillary Records	94
11.4	Recipe Management and Testing	94
11.5	EPRS Base Functionality	96
11.6	EPR Modules	97
11.7	Supplemental EPR Processes	98
11.8	Streamlining the Process	98
11.9	EPRS Approaches	99
11.10	EPRS Advantages	101
12	Appendix 8 – Review by Exception	103
12.1	Definition and Justification	103
12.2	Production Report Content Considerations	103
12.3	Considerations for New or Upgraded Systems	105
12.4	Phased Deployment	106
12.5	Periodic Systems Reassessment	106
13	Appendix 9 – Logon, Identification, and Signature Methods	107
13.1	Introduction	107
13.2	Physical Aspects	107
13.3	Logical Aspects	108
14	Appendix 10 – Human and Workflow Considerations	111
14.1	Introduction	111
14.2	Standard Interface and Enforced Operational Sequences	111
14.3	Psychological and Cultural Aspects	112
14.4	User Interface Considerations	112
15	Appendix 11 – Compliant WIP Materials Management	115
15.1	Accounting versus GxP Methods	115
15.2	Managing Material Inventory and Status	115
15.3	Dispensing (Pharmacy) and Material Consumption Considerations	116
16	Appendix 12 – Configuration Management	117
16.1	Introduction	117
16.2	Operational Definitions and Key Aspects	117
16.3	MES Domain Ownership and Life Cycle	118
16.4	Functional and Product Configuration	119
16.5	Coordinated Systems Release Processes	119
16.6	Configuration Management in an MES Domain	120
16.7	System Identification and Nomenclature	121
16.8	Installation Based Nomenclature	124
16.9	Infrastructure Tracking	125
16.10	Establishing Rules for Configuration	125

17	Appendix 13 – Standards and Models for MES	127
17.1	Introduction	127
17.2	MES Functions Address Industry Profiles.....	128
17.3	ANSI/ISA-95 Enterprise-Control System Integration	128
17.4	XML and B2MML	131
17.5	ANSI/ISA-S88	131
17.6	The Supply Chain Council SCOR Model	131
17.7	MESA International	132
18	Appendix 14 – References	133
18.1	References.....	133
18.2	Bibliography	134
19	Appendix 15 – Glossary	135
19.1	Abbreviations and Acronyms	135
19.2	Definitions	137

1 Introduction

1.1 Overview

Computerized systems are used widely throughout healthcare manufacture as a result of the substantial automation of business processes and equipment that has occurred during the 1980s and 1990s. This automation typically has occurred in an incremental system-by-system approach, over an extended period of time, which has left many organizations with islands of automation and little or no strategy for systems integration.

A traditional view of Manufacturing Execution Systems (MES) is of computerized systems designed to integrate with and extend the capabilities of other systems, e.g., by providing Recipe Management for process control equipment. The true potential of manufacturing execution lies in the integration of capabilities and functionality of systems through a well designed MES Domain, which can provide benefits, such as reduced cost, faster turnaround, and improved quality, through elimination of redundant data entry, transcription errors, etc.

This Guide uses the framework of GAMP 5, (Reference 5, Appendix 14), as a complete life cycle approach to the development and use of MES for regulated manufacturing. GAMP 5 provides a framework to:

- facilitate interpretation of regulatory requirements based on good practices
- define the approach for planning and project activities
- apply Risk Management to all aspects of the life cycle activities
- identify roles and responsibilities to execute the life cycle
- integrate existing and new systems
- scale activities and documentation appropriately
- leverage existing documentation and knowledge
- identify boundaries and interfacing among the installed systems
- develop an appropriate strategy for MES

This Guide has been developed by the Manufacturing Execution Systems Special Interest Group (MES SIG) of the GAMP Community of Practice (COP), a technical subcommittee of ISPE, to provide project teams with practical information to address the complex challenges of MES.

1.2 Purpose

This Guide is intended to provide regulated pharmaceutical organizations with the information to assist in achieving and maintaining compliant MES appropriate to the needs and capabilities of an organization.

It collects and integrates information and knowledge from many disciplines and sources into a comprehensive guideline. Regulatory requirements, industry standards, and GAMP guidance are leveraged, and references to sources of additional information are provided.

The intended audience of this document includes:

- systems and process development staff

- manufacturing technology staff
- information technology and engineering staff
- regulatory, compliance, and quality staff
- business process owners
- data owners
- suppliers of technology and systems to industry

1.3 Scope

This Guide focuses on regulated life science manufacturing industries, including:

- pharmaceuticals
- diagnostics
- biologics
- medical devices
- consumer products

It is intended to be applied to the development of new systems, to extensions of existing systems, and to the operation of systems.

Additional information about managing global IT systems may be found in the ISPE GAMP Good Practice Guide: Global Information Systems Control and Compliance (Reference 6, Appendix 14).

Although applications and examples in this document may refer to batch manufacture, the concepts, strategies, approach, and implementation presented in this Guide are applicable to manufacturing found in the medical device industry, consumer products, and packaging operations.

1.4 Benefits

The potential benefits of integrated manufacturing systems for recipe-driven operations include:

- improved scheduling and resource utilization
- improved manufacturing flexibility and process changeover
- reduced Work in Progress (WIP) and improved material tracking
- shorter production cycles
- enforced sequence of operations
- reduced production record errors, electronic or hybrid

- improved visibility, accuracy and consistency of manufacturing data, enhancing decision support, Process Analytical Technology (PAT), and investigations capabilities
- minimized product recalls
- increased plant reliability
- realize paperless manufacturing
- automated Key Performance Indicator (KPI) generation and reporting, such as an Overall Equipment Efficiency (OEE) calculation
- support knowledge management and PAT
- reduce Quality Unit resources required for day to day operations by providing functionality, such as Electronic Production Records (EPR) and Review By Exception (RBE)

This Guide aims to enable organizations to:

- shorten development and implementation times by leveraging industry experience
- implement design and testing methods that improve life cycle activities
- build compliance into the process
- provide improved understanding and coordination of the complete manufacturing environment
- reduce the risk of project failure
- better balance costs of implementation and operation
- clarify Quality Unit resources required for ongoing system operational support

1.5 Objectives

This Guide aims to provide guidance for the effective and efficient development and operation of MES by:

- providing an understanding of MES
- providing a practical framework for applying the principles and concepts of GAMP 5 to MES
- identifying regulatory and compliance aspects of MES
- providing guidance for MES suppliers
- addressing MES technical considerations

1.6 Key Concepts

1.6.1 *MES Operational Definition*

In this Guide, MES is considered to be the complete interactive system of human, electronic, and mechanized functionality to execute Manufacturing Operations. This includes the necessary business and manufacturing computer applications and systems to optimize operations, manage data, and control information flow.

This section further defines MES in the context of this Guide. These concepts have been developed from industry standards (see Appendix 13).

1.6.2 *MES Domain Concept*

This Guide considers the word 'domain' to be a method for organizing and documenting computerized systems and functions into groups or 'domains', based on common attributes, business and manufacturing goals, intended use, or risks.

The MES Domain is composed of computer systems, applications, and equipment functionality, along with any related data and information, which is used to produce desired intermediate results and final products.

The MES Domain is constructed by defining functionality necessary for production, then determining which existing or new systems or functionality are needed for implementation. An MES domain includes functionality relevant to the intended scope of manufacturing activities; this may incorporate only the necessary functionality from systems components or applications as necessary to support the domain defined by an organization. See Figure 1.1.

Figure 1.1: An Example View of MES Domain

